Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Belumosudil for chronic lung allograft dysfunction after bilateral lung transplantation
jRCT2031250734Phase 3Recruiting
- Sponsor
- Sanofi
- Start
- Mar 2026
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, double-blind trial of deuruxolitinib in chronic lung allograft dysfunction (CLAD) and Lung allograft rejection (LAR) (2 arms), sponsored by Sanofi. Primary endpoint: Percent change from baseline to Week 26 in FEV1. Started Mar 2026; status: recruiting.
02
Drugs
deuruxolitinib
03
Conditions
chronic lung allograft dysfunction (CLAD)Lung allograft rejection (LAR)
Beyond the preview
Go deeper on jRCT2031250734.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031250734.